logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma updates on Clevegen development as partner discussions advance

Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN), updates Proactive London's Andrew Scott following the release of their 2018 results.

The company's main focus recently has been on Clevegen, its cancer immunotherapy which is currently undergoing a phase I/II study.

Meanwhile a second phase III study is now planned for its Traumakine treatment, subject to approval from regulators and external funding.

Quick facts: Faron Pharmaceuticals Ltd

Price: 335 GBX

AIM:FARN
Market: AIM
Market Cap: £156.78 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO details new US Traumakine study and updates on Clevegen...

Faron Pharmaceuticals' (LON:FARN) Dr Markku Jalkanen speaks to Proactive London's Andrew Scott following a successful virtual R&D day this week. He also reports on the continued progress for two of its clinical stage programmes, Clevegen and Traumakine, including the just-announced...

2 weeks, 1 day ago

2 min read